See more : Elmera Group ASA (ELMRA.OL) Income Statement Analysis – Financial Results
Complete financial analysis of Cryoport, Inc. (CYRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cryoport, Inc., a leading company in the Integrated Freight & Logistics industry within the Industrials sector.
You may be interested
- Q32 Bio Inc. (QTTB) Income Statement Analysis – Financial Results
- Cardiff Lexington Corporation (CDIX) Income Statement Analysis – Financial Results
- Société Hôtelière et Immobilière de Nice S.A. (MLHIN.PA) Income Statement Analysis – Financial Results
- Deutsche Börse AG (DB1.DE) Income Statement Analysis – Financial Results
- STMicroelectronics N.V. (STM.PA) Income Statement Analysis – Financial Results
Cryoport, Inc. (CYRX)
About Cryoport, Inc.
Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 233.26M | 237.28M | 222.61M | 78.70M | 33.94M | 19.63M | 11.95M | 7.68M | 5.88M | 3.94M | 2.66M | 1.10M | 555.64K | 475.50K | 117.96K | 35.12K | 83.56K | 67.10K | 152.30K | 271.43K |
| Cost of Revenue | 133.92M | 133.40M | 126.03M | 42.36M | 16.59M | 9.39M | 5.99M | 4.58M | 3.99M | 2.77M | 2.22M | 1.59M | 1.39M | 1.30M | 717.71K | 546.15K | 386.37K | 176.94K | 315.65K | 499.65K |
| Gross Profit | 99.33M | 103.87M | 96.58M | 36.33M | 17.35M | 10.24M | 5.97M | 3.10M | 1.89M | 1.17M | 436.96K | -487.28K | -836.82K | -827.48K | -599.75K | -511.03K | -302.81K | -109.84K | -163.35K | -228.22K |
| Gross Profit Ratio | 42.59% | 43.78% | 43.38% | 46.17% | 51.12% | 52.18% | 49.91% | 40.39% | 32.14% | 29.70% | 16.43% | -44.28% | -150.61% | -174.02% | -508.46% | -1,454.93% | -362.37% | -163.68% | -107.26% | -84.08% |
| Research & Development | 18.04M | 15.72M | 16.84M | 9.48M | 3.74M | 1.84M | 1.21M | 598.11K | 550.26K | 352.58K | 409.11K | 425.45K | 491.85K | 449.13K | 284.85K | 297.38K | 166.23K | 87.86K | 254.49K | 98.70K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 17.47M | 9.80M | 7.42M | 6.45M | 5.93M | 6.41M | 5.11M | 5.41M | 6.11M | 4.32M | 3.31M | 2.39M | 2.55M | 1.90M | 1.02M | 622.80K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 13.82M | 7.25M | 5.23M | 4.82M | 4.16M | 2.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 146.88M | 120.06M | 97.56M | 56.86M | 31.29M | 17.04M | 12.65M | 11.27M | 10.08M | 6.41M | 5.11M | 5.41M | 6.11M | 4.32M | 3.31M | 2.39M | 2.55M | 1.90M | 1.02M | 622.80K |
| Other Expenses | 49.57M | -5.52M | -2.82M | -929.00K | 772.07K | 77.63K | 14.34K | -6.77K | -9.90K | -4.27K | -13.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -630.00 | -3.00 | 0.00 |
| Operating Expenses | 214.49M | 135.78M | 114.41M | 66.34M | 35.03M | 18.88M | 13.86M | 11.87M | 10.63M | 6.76M | 5.52M | 5.84M | 6.60M | 4.77M | 3.60M | 2.68M | 2.72M | 1.99M | 1.28M | 721.50K |
| Cost & Expenses | 348.41M | 269.18M | 240.44M | 108.71M | 51.62M | 28.27M | 19.85M | 16.44M | 14.62M | 9.53M | 7.74M | 7.42M | 7.99M | 6.07M | 4.32M | 3.23M | 3.10M | 2.16M | 1.59M | 1.22M |
| Interest Income | 0.00 | 8.47M | 3.25M | 761.00K | 784.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.94K | 15.57K | 8.16K | 32.10K | 50.08K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 5.50M | 6.14M | 4.69M | 2.56M | 1.37M | 69.25K | 15.69K | 139.42K | 1.07M | 1.43M | 784.45K | 72.86K | 527.75K | 618.77K | 7.03M | 2.69M | 1.59M | 228.37K | 80.38K | 85.77K |
| Depreciation & Amortization | 27.49M | 22.77M | 20.25M | 9.87M | 2.42M | 857.94K | 664.83K | 374.20K | 239.23K | 197.94K | 311.59K | 393.96K | 343.03K | 245.48K | 150.09K | 81.98K | 1.34M | 111.22K | 88.75K | 92.60K |
| EBITDA | -66.36M | -6.19M | -248.91M | -20.31M | -14.49M | -8.61M | -7.21M | -13.38M | -8.51M | -5.40M | -18.47M | -5.91M | -6.96M | -5.29M | 1.53M | -13.93M | -2.93M | -1.99M | -1.35M | -857.12K |
| EBITDA Ratio | -28.45% | -15.77% | -9.28% | -39.31% | -49.80% | -43.65% | -65.90% | -109.37% | -148.77% | -142.23% | -706.79% | -538.87% | -1,274.16% | -1,122.18% | -3,424.14% | -8,773.52% | -2,005.44% | -2,958.25% | -887.85% | -315.11% |
| Operating Income | -115.16M | -31.90M | -17.83M | -30.01M | -17.68M | -8.64M | -7.89M | -8.77M | -8.74M | -5.59M | -5.08M | -6.32M | -7.43M | -5.60M | -4.20M | -3.20M | -3.02M | -2.10M | -1.44M | -949.72K |
| Operating Income Ratio | -49.37% | -13.45% | -8.01% | -38.13% | -52.07% | -44.05% | -66.02% | -114.16% | -148.60% | -142.12% | -190.92% | -574.67% | -1,338.05% | -1,177.08% | -3,558.31% | -9,098.32% | -3,613.77% | -3,123.99% | -946.12% | -349.89% |
| Total Other Income/Expenses | 15.81M | -3.19M | -256.01M | -2.73M | -594.90K | -891.03K | -1.36K | -4.34M | -1.08M | -1.43M | -14.49M | -56.38K | -396.65K | -553.60K | -1.45M | -13.51M | -1.54M | -228.37K | -80.38K | -87.59K |
| Income Before Tax | -99.35M | -35.09M | -273.84M | -32.74M | -18.27M | -9.54M | -7.89M | -13.11M | -9.82M | -7.03M | -19.56M | -6.38M | -7.83M | -6.15M | -5.65M | -16.70M | -4.56M | -2.32M | -1.52M | -1.04M |
| Income Before Tax Ratio | -42.59% | -14.79% | -123.02% | -41.60% | -53.83% | -48.59% | -66.03% | -170.70% | -166.89% | -178.52% | -735.50% | -579.79% | -1,409.43% | -1,293.51% | -4,789.89% | -47,555.95% | -5,459.83% | -3,464.31% | -998.90% | -382.17% |
| Income Tax Expense | 239.00K | 2.24M | 1.69M | -45.00K | 61.58K | 19.95K | 5.14K | 5.67K | 3.63K | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | 800.00 | 800.00 |
| Net Income | -99.59M | -37.33M | -275.53M | -32.69M | -18.33M | -9.56M | -7.90M | -13.11M | -9.82M | -7.03M | -19.57M | -6.38M | -7.83M | -6.15M | -5.65M | -16.71M | -4.56M | -2.33M | -1.52M | -1.04M |
| Net Income Ratio | -42.69% | -15.73% | -123.77% | -41.54% | -54.01% | -48.69% | -66.08% | -170.77% | -166.95% | -178.56% | -735.56% | -579.94% | -1,409.72% | -1,293.84% | -4,791.25% | -47,560.50% | -5,461.75% | -3,466.70% | -999.42% | -382.46% |
| EPS | -2.21 | -0.76 | -6.00 | -0.85 | -0.55 | -0.34 | -0.34 | -0.92 | -1.34 | -1.31 | -4.48 | -1.89 | -3.03 | -5.18 | -12.63 | -45.35 | -12.96 | -8.42 | -5.70 | -6.49 |
| EPS Diluted | -2.21 | -0.76 | -6.00 | -0.85 | -0.55 | -0.34 | -0.34 | -0.92 | -1.34 | -1.31 | -4.48 | -1.89 | -3.03 | -5.18 | -12.63 | -45.35 | -12.96 | -8.42 | -5.70 | -6.49 |
| Weighted Avg Shares Out | 48.74M | 48.99M | 45.93M | 38.58M | 33.39M | 28.21M | 22.96M | 14.20M | 7.34M | 5.37M | 4.37M | 3.37M | 2.59M | 1.19M | 447.59K | 368.34K | 352.15K | 276.39K | 266.97K | 159.95K |
| Weighted Avg Shares Out (Dil) | 48.74M | 48.99M | 45.93M | 38.58M | 33.39M | 28.21M | 22.96M | 14.22M | 7.34M | 5.37M | 4.37M | 3.37M | 2.59M | 1.19M | 447.59K | 368.34K | 352.15K | 276.39K | 266.97K | 159.95K |
Cryoport Inc Shareholders Are Encouraged To Connect As The Schall Law Firm Begins An Examination Of Allegations Against It
LOS ANGELES, CA / ACCESSWIRE / July 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations...
Shareholders Of Cryoport Inc Are Urged To Get In Touch As The Schall Law Firm Is Embarking On A Review Of Claims Against It
LOS ANGELES, CA / ACCESSWIRE / July 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations...
Shareholders Of Cryoport Inc Are Called To Communicate As The Schall Law Firm Is Launching An Inquiry Into Charges Against It
LOS ANGELES, CA / ACCESSWIRE / June 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations...
Shareholders Of Cryoport Inc Are Invited To Connect As The Schall Law Firm Is Scrutinizing Accusations Against It
LOS ANGELES, CA / ACCESSWIRE / June 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations...
Cryoport Inc Shareholders Are Encouraged To Establish Communication As The Schall Law Firm Is Examining Allegations Against It
LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations...
Shareholders Of Cryoport Inc Are Encouraged To Reach Out As The Schall Law Firm Is Probing Allegations Against It
LOS ANGELES, CA / ACCESSWIRE / June 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations...
Shareholders Of Cryoport Inc Are Urged To Initiate Contact As The Schall Law Firm Is Investigating Claims Against It
LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations...
Shareholders Of Cryoport Inc Are Urged To Initiate Contact As The Schall Law Firm Is Investigating Claims Against It
LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations...
Cryoport Inc Shareholders Are Encouraged To Establish Communication As The Schall Law Firm Is Examining Allegations Against It
LOS ANGELES, CA / ACCESSWIRE / June 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations...
The Schall Law Firm Is Examining Allegations Against Cryoport Inc And Encourages Its Shareholders To Establish Communication
LOS ANGELES, CA / ACCESSWIRE / June 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations...
Source: https://incomestatements.info
Category: Stock Reports